Motley Fool
Privia Health Group CFO Sells $283,000 Worth of Shares to Cover Taxes
📊
AI Sentiment
Positive
6/10
- Home
- PRVA
as of 03-26-2026 1:09pm EST
$20.14
$0.40
-1.97%
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | ARLINGTON |
| Market Cap: | 2.8B | IPO Year: | 2021 |
| Target Price: | $31.00 | AVG Volume (30 days): | 815.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.18 | EPS Growth: | 63.64 |
| 52 Week Low/High: | $18.77 - $26.51 | Next Earning Date: | 05-07-2026 |
| Revenue: | $2,122,842,000 | Revenue Growth: | 22.26% |
| Revenue Growth (this year): | 14.66% | Revenue Growth (next year): | 10.48% |
| P/E Ratio: | 114.17 | Index: | N/A |
| Free Cash Flow: | 163.3M | FCF Growth: | +49.52% |
AI-Powered PRVA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 18 hours ago
AI Recommendation
hold
Model Accuracy: 75.76%
75.76%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Privia Health Group Inc. (PRVA)
Mountcastle David
Sell
EVP & Chief Financial Officer
PRVA Mar 16, 2026
Avg Cost/Share
$22.11
Shares
6,391
Total Value
$141,305.01
Owned After
220,413
SEC Form 4
Mehrotra Parth
Sell
Chief Executive Officer
PRVA Mar 16, 2026
Avg Cost/Share
$22.11
Shares
26,509
Total Value
$586,113.99
Owned After
555,443
SEC Form 4
Mountcastle David
Sell
EVP & Chief Financial Officer
PRVA Mar 13, 2026
Avg Cost/Share
$21.52
Shares
6,565
Total Value
$141,278.80
Owned After
220,413
SEC Form 4
Mehrotra Parth
Sell
Chief Executive Officer
PRVA Mar 13, 2026
Avg Cost/Share
$21.52
Shares
27,229
Total Value
$585,968.08
Owned After
555,443
SEC Form 4
Mountcastle David
Sell
EVP & Chief Financial Officer
PRVA Mar 12, 2026
Avg Cost/Share
$21.90
Shares
6,453
Total Value
$141,320.70
Owned After
220,413
SEC Form 4
Mehrotra Parth
Sell
Chief Executive Officer
PRVA Mar 12, 2026
Avg Cost/Share
$21.90
Shares
26,763
Total Value
$586,109.70
Owned After
555,443
SEC Form 4
Mehrotra Parth
Sell
Chief Executive Officer
PRVA Mar 10, 2026
Avg Cost/Share
$22.71
Shares
21,097
Total Value
$479,112.87
Owned After
555,443
SEC Form 4
Mountcastle David
Sell
EVP & Chief Financial Officer
PRVA Mar 9, 2026
Avg Cost/Share
$22.84
Shares
5,829
Total Value
$133,134.36
Owned After
220,413
SEC Form 4
Mehrotra Parth
Sell
Chief Executive Officer
PRVA Mar 9, 2026
Avg Cost/Share
$23.02
Shares
41,999
Total Value
$959,903.23
Owned After
555,443
Fargis Edward C
Sell
EVP & General Counsel
PRVA Mar 9, 2026
Avg Cost/Share
$22.84
Shares
4,949
Total Value
$113,035.16
Owned After
83,711
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Mountcastle David | PRVA | EVP & Chief Financial Officer | Mar 16, 2026 | Sell | $22.11 | 6,391 | $141,305.01 | 220,413 | |
| Mehrotra Parth | PRVA | Chief Executive Officer | Mar 16, 2026 | Sell | $22.11 | 26,509 | $586,113.99 | 555,443 | |
| Mountcastle David | PRVA | EVP & Chief Financial Officer | Mar 13, 2026 | Sell | $21.52 | 6,565 | $141,278.80 | 220,413 | |
| Mehrotra Parth | PRVA | Chief Executive Officer | Mar 13, 2026 | Sell | $21.52 | 27,229 | $585,968.08 | 555,443 | |
| Mountcastle David | PRVA | EVP & Chief Financial Officer | Mar 12, 2026 | Sell | $21.90 | 6,453 | $141,320.70 | 220,413 | |
| Mehrotra Parth | PRVA | Chief Executive Officer | Mar 12, 2026 | Sell | $21.90 | 26,763 | $586,109.70 | 555,443 | |
| Mehrotra Parth | PRVA | Chief Executive Officer | Mar 10, 2026 | Sell | $22.71 | 21,097 | $479,112.87 | 555,443 | |
| Mountcastle David | PRVA | EVP & Chief Financial Officer | Mar 9, 2026 | Sell | $22.84 | 5,829 | $133,134.36 | 220,413 | |
| Mehrotra Parth | PRVA | Chief Executive Officer | Mar 9, 2026 | Sell | $23.02 | 41,999 | $959,903.23 | 555,443 | |
| Fargis Edward C | PRVA | EVP & General Counsel | Mar 9, 2026 | Sell | $22.84 | 4,949 | $113,035.16 | 83,711 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 26, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 26, 2026 · 100% conf.
AI Prediction SELL
1D
-1.67%
$24.50
Act: -4.50%
5D
-5.75%
$23.48
Act: -4.30%
20D
-6.98%
$23.17
Price: $24.91 Prob +5D: 0% AUC: 1.000
0001759655-26-000007
prva-202602260001759655FALSE00017596552026-02-262026-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 2026
Privia Health Group, Inc. (Exact Name of Registrant as Specified in Its Charter)
Delaware 001-4036581-3599420 (State or other jurisdiction of incorporation or organization) (Commission File No.)(I.R.S. Employer Identification No.)
950 N. Glebe Rd., Suite 700 Arlington,Virginia22203 (Address of Principal Executive Offices) (Zip Code)
(571) 366-8850 Registrant's telephone number, including area code
Not Applicable (Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2 (b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 par value per sharePRVAThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 26, 2026, Privia Health Group, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, are “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit:
Exhibit No.Description 99.1Privia Health Group, Inc. Press Release Dated February 26, 2026
104The Cover Page from this Current Report on Form 8-K, Interactive Data File (formatted as Inline XBRL)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PRIVIA HEALTH GROUP, INC.
Date: February 26, 2026 By:/s/ David Mountcastle
Name: David Mountcastle Title: Executive Vice President, Chief Financial Officer and Authorized Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 6, 2025
0001759655-25-000108
prva-202511060001759655FALSE00017596552025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2025
Privia Health Group, Inc. (Exact Name of Registrant as Specified in Its Charter)
Delaware 001-4036581-3599420 (State or other jurisdiction of incorporation or organization) (Commission File No.)(I.R.S. Employer Identification No.)
950 N. Glebe Rd., Suite 700 Arlington,Virginia22203 (Address of Principal Executive Offices) (Zip Code)
(571) 366-8850 Registrant's telephone number, including area code
Not Applicable (Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2 (b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 par value per sharePRVAThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 6, 2025, Privia Health Group, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, are “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit:
Exhibit No.Description 99.1Privia Health Group, Inc. Press Release Dated November 6, 2025
104The Cover Page from this Current Report on Form 8-K, Interactive Data File (formatted as Inline XBRL)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PRIVIA HEALTH GROUP, INC.
Date: November 06, 2025 By:/s/ David Mountcastle
Name: David Mountcastle Title: Executive Vice President, Chief Financial Officer and Authorized Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 7, 2025
0001759655-25-000091
prva-202508070001759655FALSE00017596552025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 7, 2025
Privia Health Group, Inc. (Exact Name of Registrant as Specified in Its Charter)
Delaware 001-4036581-3599420 (State or other jurisdiction of incorporation or organization) (Commission File No.)(I.R.S. Employer Identification No.)
950 N. Glebe Rd., Suite 700 Arlington,Virginia22203 (Address of Principal Executive Offices) (Zip Code)
(571) 366-8850 Registrant's telephone number, including area code
Not Applicable (Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2 (b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.01 par value per sharePRVAThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 7, 2025, Privia Health Group, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, are “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit:
Exhibit No.Description 99.1Privia Health Group, Inc. Press Release Dated August 7, 2025
104The Cover Page from this Current Report on Form 8-K, Interactive Data File (formatted as Inline XBRL)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PRIVIA HEALTH GROUP, INC.
Date: August 07, 2025 By:/s/ David Mountcastle
Name: David Mountcastle Title: Executive Vice President, Chief Financial Officer and Authorized Officer
Latest Privia Health Group Inc. News
PRVA Breaking Stock News: Dive into PRVA Ticker-Specific Updates for Smart Investing
Compare PRVA vs Leading Stocks
See how PRVA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PRVA Privia Health Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.